Ulcerative Colitis Clinical Trial
— IBD-OWDIOfficial title:
Development and Validation of a Self-reported Objective Index of Work Disability in Inflammatory Bowel Disease
NCT number | NCT03872726 |
Other study ID # | Ref.: 2019/523 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 1, 2019 |
Est. completion date | May 30, 2019 |
Verified date | March 2019 |
Source | Corporacion Parc Tauli |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Background theme Crohn's disease (CD) and ulcerative colitis (UC) are chronic diseases that
alternate flares of active inflammation with periods of clinical remission. The working
capacity of patients may be affected both by disease activity and by the aggressive treatment
or surgical intervention required for the management of the disease and its complications.
Work disability and impairment are especially important in patients with inflammatory bowel
disease (IBD) because the disease affects young individuals who are generally employed and
fully active.
Although there are several indexes in the literature that assess the degree of work
disability due to IBD, all have a high degree of subjectivity, so none can be used to request
disability pensions.
Experience of the research group on the subject Our group has developed a line of research on
work disability associated with IBD.
Initially the investigators have studied the parameters that condition the granting of
disability pensions of Spanish courts.
Subsequently, a population study of the prevalence of work disability in Spain has been
carried out.
Finally, the investigators develop and validated a disability index for CD (published in its
extensive and reduced form) and for UC (currently under review).
Hypothesis The IBD generates a work disability that can be measured objectively. Establishing
the parameters related to disability is essential to promote equity in administrative and
judicial decisions related to the granting of disability pensions to patients with IBD.
Objective Development and validation of an objective index to measure the degree of
disability in IBD.
Material and methods:
Study 1:
A self-reported and objective questionnaire of disability will be developed based on the data
of the population survey already carried out by our group.
Patients from a previous study (n 293) will be included. The relationship of different
objective variables and disability outcomes will be analyzed with a univariate and a
subsequent multivariate analysis. Alternative work disability scores will be developed.
Study 2: for the validation of the questionnaire a new online interview will be performed,
patients from patients' assocations will be asked to participate. Data Collection: patients
will answer a online survey administered with the SurveyMonkey © platform.
Participant will answer questions about demographics, disease activity, treatment and
complications and data regarding disability. Patients will also complete the SCDWDQ (Short
Crohn's Disease Work Disability Questionnaire), Work Productivity and Activity Index (WPAI),
IBDQ-9, the EuroQol and IBD-DI (IBD disability index).
Statistical analysis: psychometric properties of the index will be evaluated:
1. Convergent validity: the Spearman correlation will be used to correlate the objective
disability score with IBD-DI and SCDWDQ.
2. Discriminant validity: it will be measured by the t-test among patients with different
degrees of disability (inactive-active, hospitalization-no hospitalization, surgery-no
surgery).
Status | Recruiting |
Enrollment | 800 |
Est. completion date | May 30, 2019 |
Est. primary completion date | May 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients between 18 and 65 years old. - Labor assets or temporary sick leave. - Diagnosis of IBD in the 6 months prior to the survey Exclusion Criteria: - Inability to understand or fill out the questionnaires. - Refusal to participate in the study. |
Country | Name | City | State |
---|---|---|---|
Spain | Luigi Melcarne | Sabadell | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Corporacion Parc Tauli |
Spain,
Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejón A, Vergara M, Campo R, Brullet E. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis. 2006 A — View Citation
Calvet X, Motos J, Montserrat A, Gallardo O, Vergara M. Analysis of court criteria for awarding disability benefits to patients with Crohn's disease. Clin Gastroenterol Hepatol. 2009 Dec;7(12):1322-7. doi: 10.1016/j.cgh.2009.01.015. Epub 2009 Feb 4. — View Citation
Ramos A, Calvet X, Sicilia B, Vergara M, Figuerola A, Motos J, Sastre A, Villoria A, Gomollón F. IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study. United European Gastroenterol J. 2015 Aug;3(4):335-42. doi: 10.1177/2050640615577532. — View Citation
Ramos A, Vergara M, Melcarne L, Sicilia B, Gomollón F, Calvet X. Validation of a self-reported work disability questionnaire for ulcerative colitis. Medicine (Baltimore). 2018 Sep;97(39):e12486. doi: 10.1097/MD.0000000000012486. — View Citation
Vergara M, Montserrat A, Casellas F, Maudsley M, Gallardo O, Ricart E, Calvet X. Validation of the Spanish Work Productivity and Activity impairment questionnaire: Crohn's disease version. Eur J Gastroenterol Hepatol. 2009 Jul;21(7):809-15. doi: 10.1097/MEG.0b013e32830f4c9e. — View Citation
Vergara M, Montserrat A, Casellas F, Villoria A, Suarez D, Maudsley M, Gallardo O, Ricart E, Calvet X. A new validation of the Spanish Work Productivity and Activity Impairment Questionnaire-Crohn's disease version. Value Health. 2011 Sep-Oct;14(6):859-61. doi: 10.1016/j.jval.2011.02.1179. Epub 2011 May 28. — View Citation
Vergara M, Sicilia B, Prieto L, Casellas F, Ramos A, Gomollón F, Calvet X. Development and Validation of the Short Crohn's Disease Work Disability Questionnaire. Inflamm Bowel Dis. 2016 Apr;22(4):955-62. doi: 10.1097/MIB.0000000000000678. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Development and validation of a self-reported objective index of disability in inflammatory bowel disease | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |